{
    "title": "Suramin vs Autism",
    "inventor_name": "Robert Naviaux et al.",
    "publication_year": null,
    "device_name": "Suramin",
    "goal": "To improve core symptoms of autism spectrum disorder by using low-dose antipurinergic therapy that modulates the cell danger response and metabolic dysfunction.",
    "problem_addressed": "Core behavioral and metabolic symptoms of autism spectrum disorder (ASD) for which no approved drugs exist.",
    "concept_summary": "A single low-dose intravenous infusion of suramin, an old antipurinergic drug, was tested in a small randomized clinical trial (SAT-1). The trial reported dramatic but transient improvements in core ASD symptoms and metabolic markers, attributed to inhibition of extracellular ATP-mediated purinergic signaling and suppression of the cell danger response. The authors propose larger trials to confirm safety and efficacy.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Antipurinergic therapy",
        "Purinergic signaling inhibition",
        "Cell danger response (CDR) modulation",
        "Metabolic syndrome correction"
    ],
    "scientific_domains": [
        "Pharmacology",
        "Neurology",
        "Metabolism",
        "Immunology"
    ],
    "mechanisms_of_action": [
        "Inhibits binding of extracellular ATP/eADP to purinergic receptors",
        "Reduces activation of the cell danger response",
        "Normalizes metabolic signaling pathways",
        "Provides a molecular \"all-clear\" safety signal"
    ],
    "materials": [
        "Suramin"
    ],
    "energy_sources": [],
    "inputs": [
        "Low-dose intravenous suramin infusion (5-15 uM blood level)",
        "Children with autism spectrum disorder"
    ],
    "outputs": [
        "Improved core ASD symptoms (social, language, repetitive behaviors)",
        "Improved metabolic biomarkers",
        "Safety outcomes (rash, infection rates)"
    ],
    "claimed_performance": "A single low-dose suramin infusion produced dramatic but transient improvement of core autism symptoms and metabolic markers, with no serious side effects observed in the small trial.",
    "experimental_evidence": "In the SAT-1 trial (10 subjects total, 5 receiving suramin), the suramin group showed significant improvements in core ASD symptoms compared with placebo, and a self-limited rash was the only observed adverse event.",
    "replication_status": "No independent replication reported; only the initial small trial.",
    "keywords": [
        "Suramin",
        "Autism",
        "Antipurinergic therapy",
        "Purinergic signaling",
        "Cell danger response",
        "Metabolic syndrome",
        "Clinical trial"
    ],
    "related_technologies": [
        "Other antipurinergic drugs",
        "Purinergic receptor antagonists",
        "Metabolic modulators"
    ],
    "controversy_level": "medium",
    "confidence_score": 0.95,
    "practicability_score": 0.7,
    "fringe_score": 0.4,
    "evidence_strength": 0.5,
    "risk_score": 0.5,
    "trl_estimate": 4,
    "source_urls": [
        "https://health.ucsd.edu/news/topics/suramin-autism/pages/default.aspx",
        "https://health.ucsd.edu/news/topics/suramin-autism/pages/q-and-a.aspx"
    ],
    "organizations": [
        "University of California San Diego School of Medicine",
        "Naviaux Lab"
    ],
    "applications": [
        "Treatment of core symptoms of autism spectrum disorder",
        "Potential therapy for other chronic diseases linked to the cell danger response"
    ],
    "limitations": [
        "Very small sample size (10 subjects, 5 treated)",
        "Transient nature of observed improvements",
        "Suramin not approved for ASD; off-label use carries regulatory risk",
        "Potential side effects (rash, unknown long-term toxicity)"
    ],
    "open_questions": [
        "Do improvements persist long-term or require repeated dosing?",
        "What is the optimal dosing schedule and duration?",
        "Are there rare adverse events that larger cohorts would reveal?",
        "Can other, more selective antipurinergic agents be more effective?"
    ],
    "red_flags": [
        "Drug not FDA-approved for autism; off-label use discouraged",
        "Evidence based on a single, under-powered trial",
        "Potential for misuse by untrained personnel"
    ],
    "evidence_quotes": [
        "A single intravenous dose of suramin produced dramatic, but transient, improvement of core symptoms of autism spectrum disorder (ASD).",
        "We did not find any serious side effects or safety concerns in this first study of a single, low-dose of suramin.",
        "The low dose that we used produced blood levels of 5-15 uM and has never been tested for any disease in the nearly 100 years that suramin has been used in medicine.",
        "After summarizing the design and results of the study, we are left with the conclusion that either the results are wrong because of the small size of the study, or they are an important advance.",
        "Suramin caused a self-limited, asymptomatic rash, but this disappeared without treatment in two to four days."
    ]
}